Literature DB >> 11755614

Tumour regression following stem cell infusion from daughter to microchimeric mother.

K Tokita1, P Terasaki, E Maruya, H Saji.   

Abstract

Fetal cells are known to persist in mothers for many years. We report a patient with poorly differentiated epithelial thymic carcinoma who had a large anterior mediastinal tumour, pericardial mass, left upper and right middle lobe tumour masses, and right liver mass. She received a single infusion of 10(10) stem cells from her 32-year-old daughter. Before the transfusion, she had had persistent chimeric cells from her daughter. The tumour regressed after stem cell infusion and has remained in regression for over 1 year. The daughter's cells were present at 330 days post infusion.

Entities:  

Mesh:

Year:  2001        PMID: 11755614     DOI: 10.1016/S0140-6736(01)07140-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Long-term feto-maternal microchimerism: nature's hidden clue for alternative donor hematopoietic cell transplantation?

Authors:  Tatsuo Ichinohe; Etsuko Maruya; Hiroh Saji
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

2.  In utero cell transfer between porcine littermates.

Authors:  Andrea McConico; Kim Butters; Karen Lien; Bruce Knudsen; Xiaosheng Wu; Jeffrey L Platt; Brenda M Ogle
Journal:  Reprod Fertil Dev       Date:  2011       Impact factor: 2.311

3.  Long-term feto-maternal microchimerism revisited: Microchimerism and tolerance in hematopoietic stem cell transplantation.

Authors:  Tatsuo Ichinohe
Journal:  Chimerism       Date:  2010 Jul-Sep

4.  Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies.

Authors:  Jon J van Rood; Cladd E Stevens; Jacqueline Smits; Carmelita Carrier; Carol Carpenter; Andromachi Scaradavou
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

5.  Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents.

Authors:  Hiromasa Yabe; Hiroyasu Inoue; Masae Matsumoto; Satoshi Hamanoue; Aiko Hiroi; Takashi Koike; Masahiro Sako; Mitsuhiro Fujiwara; Yasunori Ueda; Etsuko Maruya; Hiroh Saji; Shunichi Kato; Miharu Yabe
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

6.  Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.

Authors:  Takao Yoshihara; Keiko Okada; Michihiro Kobayashi; Atsushi Kikuta; Koji Kato; Naoto Adachi; Akira Kikuchi; Hiroyuki Ishida; Yasuzou Hirota; Hiroshi Kuroda; Yoshihisa Nagatoshi; Takeshi Inukai; Kazutoshi Koike; Hisato Kigasawa; Hiroshi Yagasaki; Kiriko Tokuda; Tomoko Kishimoto; Takahide Nakano; Naoto Fujita; Hiroaki Goto; Yozo Nakazawa; Hirokazu Kanegane; Akinobu Matsuzaki; Yuko Osugi; Daiichiro Hasegawa; Nobuhiko Uoshima; Kazuhiro Nakamura; Masahiro Tsuchida; Ryuhei Tanaka; Arata Watanabe; Hiromasa Yabe
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

Review 7.  Naturally acquired microchimerism.

Authors:  Hilary S Gammill; J Lee Nelson
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

8.  Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia.

Authors:  Nobuhiko Uoshima; Yuri Kamitsuji; Etsuko Maruya; Hiroh Saji
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies.

Authors:  Fei Zhang; Xiao-Fei Sun; Yong-Qiang Li; Zi-Jun Zhen; Hai-Xia Zheng; Jia Zhu; Qi-Jing Wang; Su-Ying Lu; Jia He; Juan Wang; Ke Pan; Rui-Qing Cai; Yan Chen; De-Sheng Weng; Fei-Fei Sun; Jian-Chuan Xia
Journal:  Chin J Cancer       Date:  2013-05-27

10.  [Comparison of the efficacy of decitabine combined with micro-transplantation or priming regimen as consolidation treatment for older patients with acute myeloid leukemia].

Authors:  W Y Li; Y F Feng; X Ma; H Y Qiu; C C Fu; X W Tang; Y Han; D P Wu; A N Sun
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.